Sonoma Pharmaceuticals (SNOA) Operating Leases (2019 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Operating Leases came in at $469000.0 in Q1 2026, up 1637.04% year-on-year from $27000.0 in Q1 2025, and down 28.4% quarter-over-quarter from $655000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Operating Leases (2019 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $469000.0 for Q1 2026.
- On a quarterly basis, Operating Leases rose 1637.04% year-over-year to $469000.0 in Q1 2026; TTM through Mar 2026 was $469000.0, a 1637.04% increase from a year earlier, with the FY2026 full-year figure at $469000.0, up 1637.04% from the prior year.
- Operating Leases declined to $469000.0 in Q1 2026 per SNOA's latest filing, from $655000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $655000.0 in Q4 2025 and bottomed at $27000.0 in Q1 2025.
- The 5-year median for Operating Leases is $309000.0 (2022), against an average of $292647.1.
- Across the five-year window, Operating Leases tumbled 86.86% in 2024 and soared 1637.04% in 2026, its largest moves.
- Year by year, Operating Leases stood at $195000.0 in 2022, then surged by 74.87% to $341000.0 in 2023, then tumbled by 65.1% to $119000.0 in 2024, then soared by 450.42% to $655000.0 in 2025, then retreated by 28.4% to $469000.0 in 2026.
- Per Business Quant, the three latest SNOA Operating Leases figures stand at $469000.0 (Q1 2026), $655000.0 (Q4 2025), and $479000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 469,000.00 |
| Dec 31, 2025 | 655,000.00 |
| Sep 30, 2025 | 479,000.00 |
| Jun 30, 2025 | 440,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 119,000.00 |
| Sep 30, 2024 | 46,000.00 |
| Jun 30, 2024 | 216,000.00 |
| Mar 31, 2024 | 87,000.00 |
| Dec 31, 2023 | 341,000.00 |
| Sep 30, 2023 | 350,000.00 |
| Jun 30, 2023 | 354,000.00 |
| Mar 31, 2023 | 162,000.00 |
| Dec 31, 2022 | 195,000.00 |
| Sep 30, 2022 | 248,000.00 |
| Jun 30, 2022 | 478,000.00 |
| Mar 31, 2022 | 309,000.00 |
| Dec 31, 2021 | 623,000.00 |
| Sep 30, 2021 | 424,000.00 |
| Jun 30, 2021 | 472,000.00 |